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Abstract 
 
Thrombocytopenia is a common occurrence 
in pregnancy. Although pregnancy is 
associated with physiological changes in 
platelet count, several pathological 
conditions cause thrombocytopenia, which 
can have a significant impact on the mother 
and the baby. There are diverse etiologies 
for thrombocytopenia, some of which are 
unique to pregnancy. This review provides a 
detailed discussion of the diagnosis and 
management of the various causes of 
thrombocytopenia in pregnancy. 
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Introduction 
Thrombocytopenia is the second 
most common hematological finding 
in pregnancy after anemia. It affects 
7-10% of all pregnant women.1 The 
normal range of platelets in non- 
pregnant women is 150,000-
400,000/µL. Thrombocytopenia is 
defined as a drop in platelet count 
below 150,000/µl. Pregnancy is 
associated with a physiological fall in 
the platelet count with a leftward shift 
in the platelet count distribution 
(Figure 1). The cause for the 
physiologic decrease in platelet 
count is multifactorial and is related 
to hemodilution, increased platelet 
consumption, and increased platelet 
aggregation driven by increased 
levels of thromboxane A2.2 Platelet 
count may also be lower in women 
with twins as compared with 
singleton pregnancies, perhaps due 
to a greater increase in thrombin 
generation.3 Pregnant women with 
thrombocytopenia tend to have fewer 
bleeding complications than non-
pregnant women due to the 
procoagulant state induced by 
increased levels of fibrinogen, factor 
VIII and von Willebrand factor, 
suppressed fibrinolysis and reduced 
protein S activity. There are several 
other pregnancy-related conditions 
that can also lead to 
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thrombocytopenia (Table 1). 
Thrombocytopenia in pregnancy is a 
common reason for hematology 
consultation. This review discusses 
the major causes of 
thrombocytopenia in pregnancy, 
including diagnostic considerations, 
management and prognosis.  
 
 
Fig 1.  Histogram of platelet counts of pregnant women in the third 
trimester (n = 6770) compared with nonpregnant women (n = 287).  (From 
Boehlen F, Hohlfield P, Extermann P: Platelet count at term pregnancy: a reappraisal of 
the threshold. Obstet Gynecol 95:29, 2000. Used with permission.) 
Gestational thrombocytopenia  
Gestational thrombocytopenia 
occurs in approximately 8% of all 
pregnancies and accounts for more 
than 70% of cases with 
thrombocytopenia in pregnancy. 
Although the pathophysiology of 
gestational thrombocytopenia is 
unknown, it is thought to be related 
to increased activation and 
peripheral consumption.4  
It is a diagnosis of exclusion, 
occurring in the later half of 
pregnancy, from the mid-second to 
third trimester. Women are typically 
asymptomatic. Platelet count is 
typically greater than 70,000/µL, with 
about two-thirds being 130,000 - 
150,000/µl.5 There is usually no past 
history of thrombocytopenia. 
Gestational thrombocytopenia can 
recur; the risk of recurrence, 
however, is unknown. 
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Table 1.  Causes of maternal thrombocytopenia in pregnancy (in 
alphabetical order). 
Pregnancy specific Non-pregnancy associated 
• Acute fatty liver  
• Gestational thrombocytopenia  
• HELLP  
• Hypertensive disorders such as 
preeclampsia/eclampsia 
 
• Autoimmune conditions such as SLE, APLS  
• Bone marrow disorders such as MDS, 
myelofibrosis  
• Disseminated intravascular coagulation 
• Drugs  
• Heparin induced thrombocytopenia 
Hypersplenism  
• Inherited, Type IIB vWD  
• Nutritional deficiencies B12, folate  
• Primary immune thrombocytopenia 
Pseudothrombocytopenia  
• Secondary immune thrombocytopenia due 
to viral infections (e.g., HIV, Hep C, CMV, 
EBV) Thrombotic microangiopathies  
• TTP/HUS 
 
Gestational thrombocytopenia 
remains a clinical diagnosis. The 
main competing diagnosis is immune 
thrombocytopenic purpura (ITP), 
which is usually considered if the 
degree of thrombocytopenia is more 
significant. However, there are 
reports of more severe 
thrombocytopenia that showed no 
response to steroids, and which 
resolved postnatally, consistent with 
gestational thrombocytopenia.6 
Unfortunately, there are no 
laboratory tests to differentiate 
between the two conditions.  The 
existence of pre-pregnancy 
thrombocytopenia should rule out 
gestational thrombocytopenia.  
However, previous pregnancies 
complicated by thrombocytopenia 
would favor gestational 
thrombocytopenia. In addition, 
response to immune modulation with 
steroids or immunoglobulins would 
favor ITP. 
During the antepartum period, no 
treatment is necessary if the patient 
is asymptomatic. Platelet count 
monitoring is recommended 
periodically, depending on the 
degree of thrombocytopenia. For 
planning labor and delivery, it may 
be helpful to obtain a platelet count 
at around 36 weeks of gestation. 
The degree of thrombocytopenia is 
generally not severe enough to 
increase the risk of bleeding with 
delivery. Patients with platelet counts 
greater than 30-50,000/µl should be 
able to undergo vaginal or surgical 
delivery safely without increased 
risk. Although epidural anesthesia is 
relatively safe with platelet count > 
50,000/µl, there remains controversy 
regarding the threshold above which 
epidural anesthesia is safe. Due to 
variations in practice, anesthesia 
consultation should be obtained prior 
to delivery to determine specific 
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anesthesia recommendations. For 
patients with significant 
thrombocytopenia, it is important to 
counsel them that their individual 
pregnancy plans may need to be 
modified depending on the platelet 
count at the time of labor. If platelet 
counts are below the acceptable 
level for anesthesia, a short course 
of steroids or intravenous 
immunoglobulins (IVIg) may be 
considered, with the thought that this 
might be a missed diagnosis of ITP.  
Gestational thrombocytopenia is self-
limiting and resolves within 1 to 2 
months after delivery. It is not 
associated with adverse outcomes 
for the baby. However, given the 
significant overlap between 
gestational thrombocytopenia and 
ITP, consideration should be made 
for evaluating the infant’s platelet 
count after delivery. 
Immune thrombocytopenic 
purpura (ITP) 
Immune thrombocytopenia occurs in 
1 in 1000-10,000 pregnancies, 
accounting for 3% of all 
thrombocytopenic gravidas.7,8 It is 
the most common cause of 
thrombocytopenia in the first and 
second trimesters.7 
ITP is an autoimmune disorder 
caused by development of 
immunoglobulin G (IgG) 
autoantibodies that are directed 
against several platelet 
glycoproteins.9 Antibody-bound 
platelets are rapidly cleared from 
maternal circulation once they bind 
to specific antibody receptors on 
macrophages, found mainly in the 
spleen and also in the liver.9 IgG 
antibodies can cross the placenta 
and have the potential to cause 
thrombocytopenia in the infant.10 
ITP is a clinical diagnosis and 
requires ruling out other causes of 
thrombocytopenia. The diagnostic 
approach is not different in pregnant 
women compared to non-pregnant 
women. Women can present with 
bruising, mucosal bleeding and 
petechiae or they may be 
asymptomatic, with the severity of 
symptoms directly proportional to the 
degree of thrombocytopenia. There 
is no specific test that differentiates 
ITP from other causes of 
thrombocytopenia. 
As primary ITP is a diagnosis of 
exclusion, causes of secondary 
thrombocytopenia such as HIV 
infection, hepatitis C and 
autoimmune disease should be ruled 
out clinically or with laboratory 
testing. ITP may be indistinguishable 
from gestational thrombocytopenia; 
however, patients with ITP usually 
have a prior history of ITP or other 
immune-mediated disorders.11-13 
Antecedent thrombocytopenia prior 
to pregnancy, persistence after 
delivery and response to ITP-
directed therapy (steroids, IVIG) 
makes ITP a more likely diagnosis.  
ITP is more likely to present with 
severe thrombocytopenia earlier on 
in pregnancy compared with 
gestational thrombocytopenia.14 
Since both gestational 
thrombocytopenia and ITP are 
clinical diagnoses and are diagnoses 
of exclusion, both deserve close 
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follow up during and after delivery. 
For both gestational 
thrombocytopenia and ITP, there 
should be no additional hematologic 
abnormalities, no microangiopathy, 
or evidence of disseminated 
intravascular coagulation (DIC) and 
liver insufficiency.  
The clinical management of the 
pregnant woman with ITP requires 
close consultation between the 
obstetrician and the hematologist. 
The decision to treat 
thrombocytopenia is determined by 
the patient’s symptoms and the level 
of thrombocytopenia. The goal of 
therapy is to prevent bleeding, and 
treatment is generally not required in 
patients with platelet counts greater 
than 20,000 to 30,000/µl if they are 
not symptomatic. If the patient is 
asymptomatic and platelet count is 
above 20,000/µl, close monitoring is 
recommended. Patients with 
thrombocytopenia should be 
evaluated for symptoms and platelet 
count monitored once a month 
during the first and second 
trimesters. The frequency of serial 
platelet count monitoring should be 
increased as term approaches or 
thrombocytopenia worsens. 
Treatment is recommended for 
women with a platelet count below 
10,000/µl at any time during 
pregnancy.15 Treatment should also 
be considered if platelet counts are 
below 30,000/µl in the third trimester 
due to the potential for imminent 
delivery. Platelet transfusion alone is 
not helpful due to the quick 
destruction of transfused platelets as 
evidenced by a poor increment in the 
post-transfusion platelet count.   
Glucocorticoids such as prednisone 
are generally the first line of therapy. 
Glucocorticoids block antibody 
production and thereby reduce the 
phagocytosis of antibody-coated 
platelets by the reticuloendothelial 
system in the spleen. The typical 
starting dose is 1 mg/kg of 
prednisone based on the pre-
pregnancy weight with a quick taper 
once a response is achieved. 
Response to therapy is not 
instantaneous, and may take several 
days to weeks. Glucocorticoids can 
cause several unique toxicities in 
pregnancy, such as gestational 
diabetes and pregnancy-induced 
hypertension. These agents may 
also be associated with premature 
rupture of fetal membranes and 
placental abruption.15 Hence, they 
should be used sparingly with the 
minimal effective doses employed.  
IVIg may be used as first line or in 
steroid resistant patients. The 
therapeutic response to IVIg is 
attributable to several different 
immunological mechanisms, 
including blockage of splenic 
macrophages.16 High dose IVIg of 1 
gm/kg over 2-5 days is effective in 
raising the platelet count rapidly; 
however, the effects are transient, 
generally lasting 1 to 4 weeks. The 
post-transfusion increment with 
platelet transfusion increases 
markedly after IVIg infusion. In life-
threatening bleeding, IVIg followed 
by platelet transfusion with or without 
steroids may be required. 
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Intravenous anti-D could be 
considered in non-splenectomized 
Rh positive patients who are 
resistant to steroids and IVIg. Anti-
RhD is a pooled IgG product taken 
from the plasma of RhD-negative 
donors who have been immunized to 
the D antigen. Anti-RhD 
immunoglobulin binds to maternal 
red blood cells. Presentation of the 
antibody-bound red blood cells to Fc 
receptors in the spleen results in 
preferential splenic phagocytosis of 
the red blood cells rather than 
platelets. Response occurs in 75% of 
patients within 1-2 days, with peak 
effect at 7-14 days and a duration of 
therapy up to 4 weeks.17 Although 
experience is limited in pregnant 
women, the response rates are 
comparable to IVIg.18 Anemia and 
jaundice in the infant have been 
reported.  
Splenectomy should be deferred if 
possible as the severity of the 
thrombocytopenia may 
spontaneously improve after 
delivery.19 It is reserved only for 
severe refractory ITP and is 
generally performed in the second 
trimester, owing to the risks of 
inducing premature labor in the first 
trimester and obstruction of the 
surgical field by the gravid uterus in 
the third trimester.1 
Rituximab is increasingly being used 
to treat ITP in non-pregnant women; 
however, it is classified as a class C 
drug in pregnancy. As information is 
limited in pregnancy it should be 
avoided unless there are no other 
options.   
Other agents used in the treatment 
of the non-pregnant women with ITP, 
such as cytotoxic and 
immunosuppressive agents, are 
discouraged during pregnancy due 
to the potential teratogenic effects. 
The thrombopoietin receptor 
agonists such as romiplostim and 
eltrombopag stimulate platelet 
production by binding to the platelet 
thrombopoietin receptor and have 
been approved for treatment of 
chronic ITP in adults. These agents 
should be avoided in pregnancy as 
there is no information on the 
reproductive effects.  
Episodes of severe bleeding are 
rare, even with very low platelets.  
The most common complication in 
the peripartum time period relates to 
the use of regional anesthesia during 
delivery. 
Vaginal delivery is the preferred 
method of delivery. Cesarean 
section should be reserved for 
obstetric indications only. The risk for 
intracranial hemorrhage in infants of 
women with ITP is very low. In 
addition, vaginal delivery does not 
increase the risk of intracranial 
hemorrhage compared to cesarean 
section.15,20 Regional anesthesia 
during labor in thrombocytopenic 
patients is controversial due to the 
increased risk of epidural hematoma; 
the decision regarding epidural 
anesthesia should be made in 
consultation with the 
anesthesiologist.21 
Thrombocytopenia in infants born to 
women with ITP is uncommon. 
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Fortunately, 90% of these infants will 
not have significant 
thrombocytopenia. Only 10% 
develop more severe 
thrombocytopenia with platelet 
counts below 50,000/µl and platelet 
counts below 20,000/µl occur in 
approximately 4% of infants.5 Even 
when severe thrombocytopenia 
occurs in the newborn, bleeding 
problems are rare and can be easily 
treated. Fetal platelet count 
monitoring with scalp sampling is 
unreliable and not recommended as 
the risks of the procedure outweigh 
the benefits. However, the platelet 
count should be measured in the 
neonate at birth and for several days 
following delivery as fetal platelet 
counts continue to drop after delivery 
with nadir 1 to 2 days.22 Pediatricians 
or primary care providers should be 
notified about the mother’s 
hematologic condition so that they 
can take appropriate steps for 
management of the infant. 
Preeclampsia 
Thrombocytopenia is usually 
moderate and platelet count rarely 
decreases to less than 20,000/µl. 
Thrombocytopenia in patients with 
preeclampsia always correlates with 
the severity of the disease.  
HELLP (hemolysis, elevated liver 
enzymes, low platelets) syndrome 
HELLP affects 0.5-0.9% of all 
pregnancies and develops in 10% of 
patients with preeclampsia.23 It is 
characterized by hemolysis, elevated 
liver enzymes and low platelets. The 
pathophysiology is similar to 
preeclampsia, with endothelial 
damage and release of tissue factor 
and coagulation activation. A recent 
study identified mutations in genes 
that regulate the alternative 
complement system, suggesting that 
excessive complement activation 
may be involved in pathogenesis 
similar to atypical hemolytic uremic 
syndrome (atypical HUS).24 
The criteria for HELLP syndrome 
vary among studies, but generally 
include microangiopathic hemolytic 
anemia, increased AST more than 
40-70 U/ml and thrombocytopenia 
with platelet counts less than 100, 
000/µl.25 HELLP syndrome may 
represent advanced preeclampsia, 
although 15-20% presenting with 
HELLP do not have antecedent 
hypertension and proteinuria. It 
occurs predominantly in the third 
trimester between 28-36 weeks of 
gestation, although a small 
percentage can occur prior to 27 
weeks .26,27 HELLP syndrome, like 
preeclampsia, can occur postpartum 
with 30% of patients presenting 
within 48 hrs of delivery. It may even 
occur up to one week after delivery. 
Unlike preeclampsia, HELLP is more 
common in multiparous women. 
Patients present with abdominal pain 
and tenderness in the epigastrium 
and right upper quadrant, which may 
be accompanied by nausea, 
vomiting and malaise. Hypertension 
and proteinuria are present in 85% of 
cases. Generalized edema precedes 
the syndrome in more than half the 
cases.27 Although thrombocytopenia 
is present, bleeding is not typical. 
HELLP can be difficult to differentiate 
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from preeclampsia; however a 
typical patient typically does have 
hypertension and proteinuria. 
Thrombocytopenia is much more 
severe in HELLP than in 
preeclampsia. Thrombotic 
microangiopathies causing 
thrombocytopenia are also difficult to 
distinguish from HELLP. The PT and 
PTT are prolonged and factors V, 
VIII and fibrinogen are decreased in 
HELLP syndrome, compared to 
thrombotic microangiopathies.  
Delivery of the fetus is the key to the 
management of HELLP. Delivery is 
indicated if pregnancy is greater than 
34 weeks gestation, there are signs 
of fetal distress and maternal 
multiorgan damage. Patients may 
require platelet transfusion if there is 
evidence of bleeding. The laboratory 
abnormalities in HELLP syndrome 
usually peak 24-48 hours following 
delivery. In the absence of other 
complications, such as renal 
dysfunction or DIC, platelet counts 
tend to rise between the fourth and 
the sixth day post-partum. When 
severe laboratory abnormalities 
persist after 72 hours, the use of 
plasma exchange and 
glucocorticoids can be considered.  
In a small study28, this approach was 
demonstrated to induce a rapid 
remission. For pregnancies fewer 
than 34 weeks gestation, where 
there is no maternal and fetal 
distress, glucocorticoids are 
recommended to accelerate fetal 
pulmonary maturity followed by 
delivery in 48 hours. Observation 
alone without a plan for delivery is 
not generally recommended because 
the condition rarely reverses until 
delivery of the baby. 
Thrombotic microangiopathies 
Thrombotic thrombocytopenic 
purpura (TTP) and hemolytic uremic 
syndrome (HUS) are collectively 
referred to as thrombotic 
microangiopathies and are not 
pregnancy specific, although they 
occur with increased frequency 
during pregnancy, with an incidence 
of 1 in 25,000 [2].29 The incidence is 
greater in the second and third 
trimesters. Patients with pregnancy-
associated TTP are at risk for 
development of recurrent TTP in 
subsequent pregnancies. 
The exact etiology is unknown, but 
endothelial damage is suspected to 
be the initiator. TTP is strongly 
associated with a severe deficiency 
of ADAMTS-13, a metalloproteinase 
that cleaves ultra-large von 
Willebrand factor (vWF) multimers, 
the most hemostatically active form 
of vWF. Deficiencies of ADAMTS-13 
are usually acquired, resulting from 
neutralizing antibodies, although 
congenital deficiency accounts for a 
minority of cases.30,31 Increased 
levels of ultra-large vWF species 
promote platelet agglutination and 
thrombotic occlusion of the 
microvasculature. 
Both TTP and HUS are essentially 
clinical diagnoses.  While assays are 
available to measure functional 
activity of ADAMTS-13 in most 
institutions, the results are not 
available in a timely enough manner 
to make them clinically useful. 
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Therefore, to make the diagnosis, 
one needs to have evidence of 
microangiopathic hemolytic anemia 
(MAHA) such as the presence of 
schistocytes, laboratory evidence of 
hemolysis and thrombocytopenia. 
Other hallmarks of advanced 
disease are neurological dysfunction, 
fever and renal insufficiency.  
The differentiation between TTP, 
HUS and HELLP can be difficult or 
even impossible, especially when the 
onset is during the second and third 
trimesters. Delivery leads to 
resolution of preeclampsia but not 
TTP/HUS. If suspected 
preeclampsia/HELLP does not 
improve within 48-72 hours after 
delivery, TTP/HUS should be 
considered. 
Plasma exchange is the first line 
therapy. Steroids have been used 
often in conjunction but are less 
effective and are associated with 
increased risk of complications in 
pregnant women. Platelet 
transfusion should be avoided, 
unless there is uncontrolled 
bleeding. Importantly, unlike 
preeclampsia and the HELLP 
syndrome, termination of pregnancy 
does not induce remission of TTP.32  
Acute fatty liver of pregnancy 
(AFLP) 
AFLP is a rare disorder with an 
incidence of 1 in 10,000-15,000 
pregnancies, maternal mortality of 
18% and fetal mortality of 23%.33,34 
Patients are usually nulliparous and 
there is an increased incidence in 
twin pregnancies.  
AFLP is thought to be due to 
abnormalities in intramitochondrial 
fatty acid beta oxidation. Maternal 
heterozygosity for long chain 3 
hydroxyacyl CoA dehydrogenase 
deficiency leads to reduced oxidation 
of the fatty acids. This combined with 
dietary factors exacerbate the 
condition. When a heterozygous 
woman carries a fetus that is 
homozygous, fetal hepatotoxic fatty 
acids accumulate and return to 
maternal circulation, causing 
maternal liver and vascular 
damage.35  
Patients usually present in the third 
trimester with nausea, vomiting, 
malaise, right upper quadrant pain 
and cholestatic liver dysfunction.36 
Laboratory findings include normal to 
low platelet count, normochromic 
normocytic anemia, elevated 
leucocyte count, prolonged 
prothrombin time, and low fibrinogen 
and antithrombin III (AT III) levels 
along with raised transaminases. 
AFLP is more likely associated with 
liver and renal failure and 
concomitant coagulopathy, 
hypoglycemia and encephalopathy 
than HELLP syndrome. 
Half of the patients will have criteria 
for preeclampsia and some may 
have features that overlap with 
HELLP. DIC is the hallmark for 
AFLP, whereas only 7% with 
preeclampsia and 20-40% with 
HELLP have DIC.  
Intensive supportive care with blood 
product support for the underlying 
coagulopathy along with immediate 
termination of pregnancy is 
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recommended as spontaneous 
recovery during pregnancy is 
unlikely. 
Miscellaneous causes of 
thrombocytopenia 
Pseudothrombocytopenia: In all 
cases of thrombocytopenia, a 
peripheral smear should be 
examined to evaluate for 
ethylenediaminetetraacetic acid 
(EDTA)-dependent platelet clumping, 
which would cause pseudo-
thrombocytopenia. In those cases, 
determination of the platelet count in 
a citrate tube should eliminate 
clumping and lead to more accurate 
readings. 
Disseminated intravascular 
coagulation: This may occur due to a 
number of reasons in pregnancy, the 
most common being placental 
abruption, amniotic fluid embolism 
and uterine rupture. There is 
profound activation of the 
coagulation system due to the rapid 
release of tissue factor-rich material 
into the maternal circulation, leading 
to consumption of the coagulation 
factors and hypofibrinogenemia. It is 
associated with prolonged PT/PTT, 
thrombocytopenia, low fibrinogen, 
elevated fibrin degradation products 
and the presence of D dimers. DIC 
may also occur with retained 
products of conception, where it is 
more gradual in onset, and 
thrombocytopenia may be the 
presenting feature.37 
Nutritional deficiencies: Severe folic 
acid and B12 deficiency may cause 
low platelet count, but is usually 
accompanied by low red blood cell 
and leucocyte counts. These are 
however rare in pregnancy as 
women receive folic acid 
supplementation to prevent neural 
tube defects. Vitamin B12 deficiency 
is rare in pregnancy because those 
with established B12 deficiency are 
subfertile. 
Heparin induced thrombocytopenia 
(HIT): This entity has been described 
very rarely in pregnancy. There is 
only 1 case reported in 3 studies; 
hence, routine monitoring is not 
required for patients receiving 
prophylactic low molecular weight 
heparin.38 As HIT is intensely 
prothrombotic despite 
thrombocytopenia, alternative 
anticoagulation is required to prevent 
further thrombosis. Treatment 
modalities include withdrawal of 
unfractionated heparin or low 
molecular weight heparin and 
replacement with alternative 
anticoagulants such as direct 
thrombin inhibitors (argatroban, 
dabigatran) and fondaparinux. 
Fondaparinux has been used in 
pregnancy in a few case reports.39 
All these drugs are class B in 
pregnancy and should be used with 
caution.  
Type 2B von Willebrand disease: 
This is a subtype of vWD, which is 
associated with increased affinity of 
vWF binding to platelet receptor 
glycoprotein 1b. This augmented 
binding induces spontaneous platelet 
aggregation, accelerates platelet 
clearance and hence causes 
thrombocytopenia. During pregnancy 
there is a physiological increase in 
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the mutant vWF levels, and the 
thrombocytopenia induced by the 
mutant vWF may become more 
apparent. The platelet count may fall 
to a low as 20,000 to 30,000/µl. 
Hematology consultation for the 
management of these patients is 
essential. 
Marrow infiltrative disorders: These 
are unlikely in women of child 
bearing age. Bone marrow biopsy 
may be indicated if the diagnosis is 
suspected. The management plan 
would depend on the exact 
diagnosis, stage of pregnancy and 
the risks to the mother by delaying 
treatment. 
Autoimmune disease such as 
systemic lupus erythematosus and 
antiphospholipid syndrome: These 
disorders are characterized by 
vascular thrombosis and pregnancy 
complications, with secondary 
immune thrombocytopenia as a 
potential manifestation of the 
disorder. The thrombocytopenia is 
less severe than seen with ITP. 
Treatment is similar to ITP for severe 
symptomatic thrombocytopenia.  
Other inherited thrombocytopenias: 
Congenital disorders such as May 
Hegglin anomaly and Bernard 
Soulier and Glanzmann’s 
thrombasthenia are rare but may be 
detected during pregnancy through 
platelet aggregation studies and 
identification of abnormal platelet 
morphology on review of the blood 
smear.  
Conclusions 
Although thrombocytopenia during 
pregnancy is common, it is not 
frequently severe. However 
awareness of the complex disorders 
is essential. A thorough history and 
physical examination is important to 
rule out major causes. Management 
of pregnant women with 
thrombocytopenia requires a 
multidisciplinary approach with a 
close collaboration between the 
hematologist and the obstetrician. 
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